EA201590062A1 - Применение лимонно-кислого железа при лечении пациентов с хронической почечной недостаточностью - Google Patents
Применение лимонно-кислого железа при лечении пациентов с хронической почечной недостаточностьюInfo
- Publication number
- EA201590062A1 EA201590062A1 EA201590062A EA201590062A EA201590062A1 EA 201590062 A1 EA201590062 A1 EA 201590062A1 EA 201590062 A EA201590062 A EA 201590062A EA 201590062 A EA201590062 A EA 201590062A EA 201590062 A1 EA201590062 A1 EA 201590062A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- iron
- increase
- patients
- reduce
- chronic
- Prior art date
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title abstract 10
- 229910052742 iron Inorganic materials 0.000 title abstract 5
- 239000002253 acid Substances 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 210000002966 serum Anatomy 0.000 abstract 2
- HUTBITLDXCEAPZ-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;iron Chemical compound [Fe].OC(=O)CC(O)(C(O)=O)CC(O)=O HUTBITLDXCEAPZ-UHFFFAOYSA-N 0.000 abstract 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract 1
- 102000008857 Ferritin Human genes 0.000 abstract 1
- 108050000784 Ferritin Proteins 0.000 abstract 1
- 238000008416 Ferritin Methods 0.000 abstract 1
- 102000001554 Hemoglobins Human genes 0.000 abstract 1
- 108010054147 Hemoglobins Proteins 0.000 abstract 1
- 206010022971 Iron Deficiencies Diseases 0.000 abstract 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 230000010437 erythropoiesis Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 239000011574 phosphorus Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Раскрыты способы введения лимонно-кислого железа для уменьшения и/или контроля уровня фосфора в крови, увеличения уровней бикарбоната в сыворотке, повышения одного или нескольких параметров накопления железа (например, увеличение концентрации ферритина в сыворотке крови, увеличение насыщения трансферрина (TSAT), увеличение концентрации гемоглобина), увеличения усвоения железа, поддержания запасов железа в организме, лечения дефицита железа, лечения анемии, снижения потребности в железе IV и/или снижения потребности в эритропоэз-стимулирующих веществах (ESA) у пациентов с хронической почечной недостаточностью.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261662565P | 2012-06-21 | 2012-06-21 | |
US201361757229P | 2013-01-28 | 2013-01-28 | |
US201361800618P | 2013-03-15 | 2013-03-15 | |
US201361801050P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/047134 WO2013192565A2 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201590062A1 true EA201590062A1 (ru) | 2016-02-29 |
Family
ID=49769729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201590062A EA201590062A1 (ru) | 2012-06-21 | 2013-06-21 | Применение лимонно-кислого железа при лечении пациентов с хронической почечной недостаточностью |
Country Status (17)
Country | Link |
---|---|
US (3) | US20130345303A1 (ru) |
EP (3) | EP3730136B1 (ru) |
JP (4) | JP2015535209A (ru) |
KR (2) | KR20200103855A (ru) |
CN (2) | CN104884055A (ru) |
AU (2) | AU2013278000A1 (ru) |
BR (1) | BR112014032049A2 (ru) |
CA (1) | CA2876982A1 (ru) |
DK (1) | DK3730136T3 (ru) |
EA (1) | EA201590062A1 (ru) |
ES (2) | ES2970050T3 (ru) |
HK (2) | HK1210013A1 (ru) |
IL (1) | IL236356A0 (ru) |
MX (1) | MX2014015615A (ru) |
PL (1) | PL3730136T3 (ru) |
SG (2) | SG11201408521WA (ru) |
WO (1) | WO2013192565A2 (ru) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108938585A (zh) | 2009-07-21 | 2018-12-07 | 凯克斯生物制药公司 | 柠檬酸铁剂型 |
TWI653043B (zh) * | 2012-12-20 | 2019-03-11 | 瑞士商伊蘭科動物健康公司 | 新用途 |
ES2646271T3 (es) | 2013-06-05 | 2017-12-13 | Tricida Inc. | Polímeros de unión de protones para la administración oral |
ES2856261T3 (es) * | 2013-10-01 | 2021-09-27 | Fresenius Medical Care Deutschland Gmbh | Método y aparatos para determinar una pérdida diaria de hierro de un paciente |
CA2928200A1 (en) * | 2013-11-04 | 2015-05-07 | Keryx Biopharmaceuticals, Inc. | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
WO2015110968A1 (en) * | 2014-01-23 | 2015-07-30 | Lupin Limited | Pharmaceutical grade ferric citrate and method for its production |
US10172882B2 (en) | 2014-06-22 | 2019-01-08 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
LT3229816T (lt) | 2014-12-10 | 2020-05-25 | Tricida Inc. | Protoną prijungiantys polimerai, skirti peroraliniam įvedimui |
WO2016141124A1 (en) * | 2015-03-04 | 2016-09-09 | Keryx Biopharmaceuticals, Inc. | Use of ferric citrate in the treatment of iron-deficiency anemia |
CN104688706B (zh) * | 2015-04-01 | 2017-07-14 | 成都欣捷高新技术开发有限公司 | 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法 |
WO2016162794A1 (en) * | 2015-04-08 | 2016-10-13 | Leiutis Pharmaceuticals Pvt Ltd | Pharmaceutical compositions of ferric citrate |
WO2016162888A1 (en) * | 2015-04-09 | 2016-10-13 | Actavis Group Ptc Ehf. | Process for preparing pharmaceutical grade ferric citrate |
MA44875A (fr) | 2016-05-06 | 2019-03-13 | Tricida Inc | Compositions pour le traitement de troubles acido-basiques |
JP7387435B2 (ja) | 2017-09-19 | 2023-11-28 | 日本たばこ産業株式会社 | 過多月経患者及び/又は過多月経を伴う婦人科疾患を有する患者における鉄欠乏性貧血の予防及び/又は治療におけるクエン酸第二鉄の使用 |
AU2018360867A1 (en) | 2017-11-03 | 2020-04-30 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
WO2019236639A1 (en) * | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
JP2022505697A (ja) * | 2018-10-29 | 2022-01-14 | ファーマコスモス ホールディング エー/エス | カルボキシマルトース第二鉄による鉄欠乏症の治療 |
WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
CN117999069A (zh) | 2021-05-27 | 2024-05-07 | 凯克斯生物制药公司 | 柠檬酸铁的儿科调配物 |
CN115024495B (zh) * | 2022-06-27 | 2024-03-22 | 北京金康普食品科技有限公司 | 改善肾病患者钙磷代谢的营养组合物及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180094B1 (en) * | 1996-07-19 | 2001-01-30 | Nikken Chemicals Co., Ltd. | Remedies for hyperphosphatemia |
US5753706A (en) * | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
US8093423B2 (en) | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
CN1600302A (zh) * | 2003-09-22 | 2005-03-30 | 宝龄富锦生技股份有限公司 | 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品 |
US20060134227A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
MX2008002360A (es) | 2005-08-18 | 2008-04-29 | Globoasia Llc | Compuestos organicos ferricos grado farmaceutico, uso de los mismos y metodos para elaborar los mismos. |
CA2635894C (en) * | 2006-01-06 | 2017-09-12 | Luitpold Pharmaceuticals, Inc. | Methods and compositions for administration of iron |
ES2580127T3 (es) | 2006-01-30 | 2016-08-19 | Panion & Bf Biotech Inc. | Procedimiento de tratamiento de la nefropatía crónica |
CN108938585A (zh) * | 2009-07-21 | 2018-12-07 | 凯克斯生物制药公司 | 柠檬酸铁剂型 |
-
2013
- 2013-06-21 ES ES20163104T patent/ES2970050T3/es active Active
- 2013-06-21 BR BR112014032049A patent/BR112014032049A2/pt not_active IP Right Cessation
- 2013-06-21 CA CA2876982A patent/CA2876982A1/en not_active Abandoned
- 2013-06-21 EA EA201590062A patent/EA201590062A1/ru unknown
- 2013-06-21 KR KR1020207024260A patent/KR20200103855A/ko not_active IP Right Cessation
- 2013-06-21 EP EP20163104.1A patent/EP3730136B1/en active Active
- 2013-06-21 WO PCT/US2013/047134 patent/WO2013192565A2/en active Application Filing
- 2013-06-21 JP JP2015518623A patent/JP2015535209A/ja active Pending
- 2013-06-21 AU AU2013278000A patent/AU2013278000A1/en not_active Abandoned
- 2013-06-21 SG SG11201408521WA patent/SG11201408521WA/en unknown
- 2013-06-21 DK DK20163104.1T patent/DK3730136T3/da active
- 2013-06-21 EP EP13807102.2A patent/EP2863906B1/en active Active
- 2013-06-21 KR KR1020157001458A patent/KR102150135B1/ko active IP Right Grant
- 2013-06-21 CN CN201380044271.0A patent/CN104884055A/zh active Pending
- 2013-06-21 US US13/924,332 patent/US20130345303A1/en not_active Abandoned
- 2013-06-21 ES ES13807102T patent/ES2796254T3/es active Active
- 2013-06-21 MX MX2014015615A patent/MX2014015615A/es unknown
- 2013-06-21 SG SG10201805177PA patent/SG10201805177PA/en unknown
- 2013-06-21 CN CN202110644193.4A patent/CN113244209A/zh active Pending
- 2013-06-21 PL PL20163104.1T patent/PL3730136T3/pl unknown
- 2013-06-21 EP EP23219273.2A patent/EP4335436A3/en active Pending
-
2014
- 2014-04-25 US US14/262,465 patent/US20140234416A1/en not_active Abandoned
- 2014-10-24 US US14/523,656 patent/US20150079168A1/en not_active Abandoned
- 2014-12-18 IL IL236356A patent/IL236356A0/en unknown
-
2015
- 2015-10-28 HK HK15110673.6A patent/HK1210013A1/xx unknown
-
2016
- 2016-03-01 HK HK16102352.0A patent/HK1214503A1/zh unknown
-
2018
- 2018-04-10 JP JP2018075243A patent/JP2018138562A/ja active Pending
- 2018-05-08 AU AU2018203205A patent/AU2018203205B2/en not_active Ceased
-
2020
- 2020-02-25 JP JP2020029756A patent/JP2020100638A/ja active Pending
-
2022
- 2022-02-10 JP JP2022019167A patent/JP2022070945A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201590062A1 (ru) | Применение лимонно-кислого железа при лечении пациентов с хронической почечной недостаточностью | |
MX2016005734A (es) | Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica. | |
MX2017010734A (es) | Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos. | |
WO2013132498A3 (en) | Inhalation of nitric oxide for treating respiratory diseases | |
EA201590849A1 (ru) | Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови | |
EA201070553A1 (ru) | Антитела к гепцидину и варианты их применения | |
WO2009125300A3 (en) | Oxygenation procedures for newborns and devices for use therein | |
MX2016016531A (es) | Metodos y composiciones para el tratamiento de las ulceras. | |
MX2014011186A (es) | Metodo para mejorar la eficiencia de las transfusiones de sangre. | |
EA201492106A1 (ru) | Способ и устройство для контроля экстракорпоральной обработки крови пациента | |
EA201591424A1 (ru) | Способы лечения дефицита железа растворимым пирофосфатом железа | |
MX361881B (es) | Prediccion y optimizacion de terapia de potasio en suero para terapia de sangre para insuficiencia renal, especialmente hemodialisis domiciliaria. | |
EA201990403A1 (ru) | Человеческие анти-vegfr-2/kdr-антитела | |
WO2010119991A3 (en) | Anti-hgf antibody combinational cancer therapies | |
WO2012058585A3 (en) | Treatment of heart failure with natriuretic peptides | |
BR112013009660A8 (pt) | Proteína de fusão com fator de atividade ix, sequência de dna e vetor recombinante | |
BR112014009414A2 (pt) | uso de micelas de proteína de soro do leite para melhorar o perfil de insulina em pacientes diabéti-cos | |
WO2013142153A3 (en) | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics | |
WO2014049438A3 (en) | Method of non-invasive determination of glucose concentration in blood and device for the implementation thereof | |
UA62757U (ru) | Способ прогнозирования адекватности программного гемодиализа у больных с хронической болезнью почек v стадии | |
UA58034U (ru) | Способ оценки риска развития осложнений течения хронической болезни почек у больных, которых лечат программным гемодиализом | |
NZ725920A (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
UA80889U (ru) | Способ дифференциальной диагностики анемий у больных с хроническими заболеваниями внутренних органов | |
RU2013110191A (ru) | Способ определения предикторной значимости мозгового натрийуретического пептида у больных хронической болезнью почек, получающих терапию программным гемодиализом | |
范凯文 et al. | A study of effects of using low dialysate calcium concentration (1.50 mmol/L) on blood pressure, serum concentrations of calcium, parathyroid hormone and aldosterone in chronic hemodialysis patients |